Draupnir Holding B.V. successfully places 1,500,000 shares of PolyPeptide Group AG

Niederer Kraft Frey advised Draupnir Holding B.V. (“Draupnir) in connection with the sale of 1,500,000 existing ordinary shares in PolyPeptide Group AG (“PolyPeptide”) in private placements to institutional investors by way of an accelerated bookbuilding process. The shares, which represent approximately 4.5 per cent. of PolyPeptide’s share capital, were placed at a price of CHF 114 per share, raising aggregate gross proceeds of CHF 171 million for Draupnir. Following settlement of the placement on 12 November 2021, Draupnir continues to hold approximately 55.5 per cent. of PolyPeptide’s share capital.

Credit Suisse AG and Morgan Stanley Europe SE acted as joint bookrunners in connection with the offering.

The NKF team was led by Corporate/Capital Markets partner Philippe Weber, working with senior associate Franziska Albers-Schönberg.